Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: J Med Chem. 2020 Jan 30;63(4):1624–1641. doi: 10.1021/acs.jmedchem.9b01502

Figure 4.

Figure 4.

Evaluating biological potency of SRC inhibitors in lung and breast cancer cell lines. (A) Comparing growth inhibitory potency of 15a in H1975 (nonsmall cell lung cancer, NSCLC), HCC827 (NSCLC), and MDA-MB-231 (triple negative breast cancer, TNBC) cell lines. (B) Comparing growth inhibitory potency of 15a, 20f, and AZD0530 across cell lines. Growth inhibition was carried out by treating cells with different concentrations of 15a, 20f, or AZD0530 for 72 h, followed by analysis using the CellTiter-Glo reagent. Dose–response curves and the corresponding GR values were calculated using the online tool GR calculator (http://www.grcalculator.org/grcalculator/). Both the curves and the GR50 values are representative of two independent experiments, each carried out in technical triplicate.